An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016–present)

References

• Paratcha G, Ledda F. GDNF and GFRα: a versatile molecular complex for developing neurons. Trends Neurosci. 2008;31(8):384–391.
   PubMed Web of Science ®Google Scholar
• Jain S, Naughton CK, Yang M, et al. Mice expressing a dominant-negative Ret mutation phenocopy human Hirschsprung disease and delineate a direct role of Ret in spermatogenesis. Development. 2004;131(21):5503–5513.
   PubMed Web of Science ®Google Scholar
• Fonseca-Pereira D, Arroz-Madeira S, Rodrigues-Campos M, et al. The neurotrophic factor receptor RET drives haematopoietic stem cell survival and function. Nature. 2014;514(7520):98–101.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Buma Y, Iwamoto T, et al. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene. 1988;3(5):571–578.
   PubMed Web of Science ®Google Scholar
• Anders J, Kjær S, Ibáñez CF. Molecular Modeling of the Extracellular Domain of the RET Receptor Tyrosine Kinase Reveals Multiple Cadherin-like Domains and a Calcium-binding Site *. J Biol Chem. 2001;276(38):35808–35817.
   PubMed Web of Science ®Google Scholar
• Wang X. Structural studies of GDNF family ligands with their receptors—Insights into ligand recognition and activation of receptor tyrosine kinase RET. Biochim Biophys Acta Proteins Proteom. 2013;1834(10):2205–2212.
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005;16(4):441–467.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li Y, Liu C, et al. Identification of a novel KIF13A-RET fusion in lung adenocarcinoma by next-generation sequencing. Lung Cancer. 2018;118:27–29.
   PubMed Web of Science ®Google Scholar
• Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol. 2016;12(4):192–202.
   PubMed Web of Science ®Google Scholar
• Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5(1):3116.
   PubMedGoogle Scholar
• Drilon A, Hu ZI, Lai GGY, et al. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes. Nat Rev Clin Oncol. 2018;15(3):151–167.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Yang D, Velcheti V, et al. State-of-the-Art Strategies for Targeting RET-Dependent Cancers. J Clin Oncol. 2020;38(11):1209–1221.
   PubMed Web of Science ®Google Scholar
• Wiesenhofer B, Stockhammer G, Kostron H, et al. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-α1) are strongly expressed in human gliomas. Acta Neuropathol. 2000;99(2):131–137.
   PubMed Web of Science ®Google Scholar
• Flavin R, Finn SP, Choueiri TK, et al., RET protein expression in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2012, 30, 900–905.
   Google Scholar
• Lin C, Lu W, Ren Z, et al. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma. Cancer Lett. 2016;377(1):1–10.
   PubMed Web of Science ®Google Scholar
• Russell JP, Mohammadi E, Ligon CO, et al. Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: a Preclinical Investigation in Rodent Models of Colonic Hypersensitivity. J Pharmacol Exp Ther. 2019;368(2):299.
   PubMed Web of Science ®Google Scholar
• Bradford D, Larkins E, Mushti SL, et al. Selpercatinib for the treatment of lung and thyroid cancers with ret gene mutations or fusions. Clin Cancer Res. 2021;27(8):2130–2135.
   PubMed Web of Science ®Google Scholar
• Kim J, Bradford D, Larkins E, et al. Pralsetinib for the treatment of lung and thyroid cancers with ret gene mutations or fusions. Clin Cancer Res. 2021;27(20):5452–5456.
   PubMed Web of Science ®Google Scholar
• DeMartino M, Guan HA. Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer. US10111866B2, 2017.
   Google Scholar
• Schenck Eidam H, Russell J, Raha K, et al. Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS. ACS Med Chem Lett. 2018;9(7):623–628.
   PubMed Web of Science ®Google Scholar
• Andrews SW, Aronow S, Blake JF, et al. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors. 2018.
   Google Scholar
• Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869–1876.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Shen T, Terzyan SS, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021;32(2):261–268.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Gainor JF, Oxnard GR, et al. , Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. J Clin Oncol. 2020;38(15):9516–9586.
   Web of Science ®Google Scholar
• Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer. N Engl J Med. 2020;383(9):813–824.
   PubMed Web of Science ®Google Scholar
• Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825–835.
   PubMed Web of Science ®Google Scholar
• FDA approves selpercatinib for lung and thyroid cancer with RET gene mutations or fusions. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selpercatinib-lung-and-thyroid-cancers-ret-gene-mutations-or-fusions.
   Google Scholar
• Walls SM, Ren L, Ramann GA, et al. Substituted pyrazolyl[4,3-c] pyridine compounds as RET kinase inhbitors. 2019.
   Google Scholar
• Li Q, Zhang J, Jian S, et al. Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof. 2020.
   Google Scholar
• Fordyce EAF, Hynd G, Allan J, et al. Heterocyclic compounds as RET kinase inhibitors. 2021.
   Google Scholar
• He C, Tan R, Zhou Z, et al. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors. 2020.
   Google Scholar
• Tan R, Zhao X, Linghu L, et al. Substituted [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors. 2020.
   Google Scholar
• Liu T-C, Peng X, Ma Y-C. Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors. Acta Pharmacologica Sinica. 2016;37(5):698–707.
   PubMed Web of Science ®Google Scholar
• Andrews SW, Blake JF, Haas J, et al.; Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors. US11168090B2, 2018.
   Google Scholar
• Brubaker JD, Kim JL, Wilson KJ, et al. Inhibitors of RET. 2016.
   Google Scholar
• Markham A. Pralsetinib: first Approval. Drugs. 2020;80(17):1865–1870.
   PubMed Web of Science ®Google Scholar
• FDA approves pralsetinib for lung cancer with gene fusions. [cited 2022 Apr 23]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pralsetinib-lung-cancer-ret-gene-fusions.
   Google Scholar
• Kato S, Subbiah V, Marchlik E, et al. RET Aberrations in Diverse Cancers: next-Generation Sequencing of 4,871 Patients. Clin Cancer Res. 2017;23(8):1988–1997.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Tan L, Lin JJ, et al. mutations mediate acquired resistance to selective ret inhibition in ret-driven malignancies. J Thorac Oncol. 2020;15(4):541–549.
   PubMed Web of Science ®Google Scholar